NAVIDEA BIOPHARMACEUTICALS, INC.
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB): 5 pipeline candidates · ~1 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
1.2 months
D/E -2.65 · 0% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for NAVIDEA BIOPHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$3.9M
Quarterly Burn
$10.2M
Runway
1.2 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| man-bis | Preclinical |
| man-dex | Preclinical |
| man-dox | Preclinical |
| man-pac | Preclinical |
| tc99m tilmanocept | Phase 3 |
Frequently asked questions
How many drug candidates are in NAVIDEA BIOPHARMACEUTICALS, INC.'s pipeline?
NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is NAVIDEA BIOPHARMACEUTICALS, INC.'s lead drug candidate?
NAVIDEA BIOPHARMACEUTICALS, INC.'s most advanced tracked candidate is man-bis (Preclinical) for Cancer.
What is NAVIDEA BIOPHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, NAVIDEA BIOPHARMACEUTICALS, INC. has approximately 1.2 months of cash runway.
Who is the CEO of NAVIDEA BIOPHARMACEUTICALS, INC.?
Swing Foundation is the chief executive officer of NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB).
Get the full picture on NAVIDEA BIOPHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.